TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV
Brief Summary: Rotavirus (RV) is the most important cause of acute gastroenteritis (GE) requiring the hospitalization of infants and young children in developed and developing countries and can be a frequent cause of death in children less than 5 years of age (estimated nearly 500,000 annual deaths worldwide). GlaxoSmithKline (GSK) Biologicals has developed a vaccine against human rotavirus gastroenteritis. A new formulation of the vaccine, with an alternative buffer, was developed. This study will be conducted to evaluate the new formulation compared to the existing formulation of the HRV vaccine.


Options:
A: Intervention Type: BIOLOGICAL; Name: Live attenuated rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1
D: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV
Brief Summary: Rotavirus (RV) is the most important cause of acute gastroenteritis (GE) requiring the hospitalization of infants and young children in developed and developing countries and can be a frequent cause of death in children less than 5 years of age (estimated nearly 500,000 annual deaths worldwide). GlaxoSmithKline (GSK) Biologicals has developed a vaccine against human rotavirus gastroenteritis. A new formulation of the vaccine, with an alternative buffer, was developed. This study will be conducted to evaluate the new formulation compared to the existing formulation of the HRV vaccine.


Options:
A: Arm Label: Bivalent OPV 2 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 2 week interval | Arm Label: Bivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 4 week interval | Arm Label: Monovalent OPV 2week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 2 week interval | Arm Label: Monovalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 4 week interval | Arm Label: Trivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 2 week interval; Assigned to Arm(s): Bivalent OPV 2 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 4 week interval; Assigned to Arm(s): Bivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 2 week interval; Assigned to Arm(s): Monovalent OPV 2week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 4 week interval; Assigned to Arm(s): Monovalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Trivalent OPV 4 week interval; Assigned to Arm(s): Trivalent OPV 4 week interval
B: Intervention Type: BIOLOGICAL; Name: Live attenuated rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: Breastfeeding; Type: OTHER; Interventions: Other: Breastfeeding | Arm Label: Breastfeeding Withheld; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding, Breastfeeding Withheld
D: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parents Matter!: Interventions to Promote Effective Parent-Child Communication About Sex and Sexual Risk Among African American Families
Brief Summary: Parents Matter is a community-based project whose goal it is to develop and test an intervention designed to promote effective parent-child communication about sexuality in order to promote sexual health among adolescents.


Options:
A: Arm Label: SAFE Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SAFE Behavioral Intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: SAFE Behavioral Intervention; Assigned to Arm(s): SAFE Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
D: Intervention Type: BEHAVIORAL; Name: Full Parent communication intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Brief Parent Communication Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Control Parent Intervention; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes
Brief Summary: This is a 52-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to metformin in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar. The purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin
C: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin | Arm Label: Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide, Drug: Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1.5 mg LY2189265, Liraglutide
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of Internal Globus Pallidus or Median Centre of the Thalamus High Frequency Stimulation for the Treatment of Patients With Severe Tourette's Syndrome
Brief Summary: Tourette's syndrome is a disabling neuropsychiatric disorder with major psychosocial consequences in some patients. The pathophysiology is still unknown. Some data suggest an dysfunction of limbic circuits in basal ganglia. The aim of this study is to evaluate the effect of high frequency stimulation of the internal part of the globus pallidus and/or parafascicular-median centre of the thalamus, two structures implicated in the limbic circuit, in patients with severe Tourette's syndrome.


Options:
A: Arm Label: DBS Off first; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral GPi Deep Brain Stimulation | Arm Label: DBS On First; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral GPi Deep Brain Stimulation | Intervention Type: PROCEDURE; Name: Bilateral GPi Deep Brain Stimulation; Assigned to Arm(s): DBS Off first, DBS On First
B: Intervention Type: DEVICE; Name: high frequency stimulation; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Other: Deep brain stimulation | Arm Label: Deep Brain Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Deep brain stimulation | Intervention Type: OTHER; Name: Deep brain stimulation; Assigned to Arm(s): Deep Brain Stimulation, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Deep brain stimulation | Intervention Type: DEVICE; Name: Deep brain stimulation; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh
Brief Summary: The main objective of this study is to provide immunogenicity data for GSK Biologicals' HRV vaccine when co-administered with OPV or when given alone (HRV vaccine dose given 15 days after the OPV dose).


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group
C: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation
D: Arm Label: Rotavirus vaccine (BRV-PV); Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine (BRV-PV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine (BRV-PV); Assigned to Arm(s): Rotavirus vaccine (BRV-PV) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh
Brief Summary: The main objective of this study is to provide immunogenicity data for GSK Biologicals' HRV vaccine when co-administered with OPV or when given alone (HRV vaccine dose given 15 days after the OPV dose).


Options:
A: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
B: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
D: Arm Label: Cohort A P2-VP8 30 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort A P2-VP8 60 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort B P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Arm Label: Cohort B placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort B P2-VP8 30mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort B1 P2-VP8 60mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort A P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 10mcg; Assigned to Arm(s): Cohort A P2-VP8 10mcg, Cohort B P2-VP8 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 30 mcg; Assigned to Arm(s): Cohort A P2-VP8 30 mcg, Cohort B P2-VP8 30mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 60mcg; Assigned to Arm(s): Cohort A P2-VP8 60 mcg, Cohort B1 P2-VP8 60mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort B placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh
Brief Summary: The main objective of this study is to provide immunogenicity data for GSK Biologicals' HRV vaccine when co-administered with OPV or when given alone (HRV vaccine dose given 15 days after the OPV dose).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
D: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
Brief Summary: The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.


Options:
A: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
Brief Summary: The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.


Options:
A: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
B: Arm Label: Group A (without rotavirus vaccine); Type: ACTIVE_COMPARATOR; Interventions: Biological: measles vaccine (MV), Biological: yellow fever vaccine (YFV), Biological: meningitis conjugate vaccine (PsA-TT-5μg) | Arm Label: Group B (with rotavirus vaccine); Type: EXPERIMENTAL; Interventions: Biological: pentavalent rotavirus vaccine (PRV), Biological: measles vaccine (MV), Biological: yellow fever vaccine (YFV), Biological: meningitis conjugate vaccine (PsA-TT-5μg) | Intervention Type: BIOLOGICAL; Name: pentavalent rotavirus vaccine (PRV); Assigned to Arm(s): Group B (with rotavirus vaccine) | Intervention Type: BIOLOGICAL; Name: measles vaccine (MV); Assigned to Arm(s): Group A (without rotavirus vaccine), Group B (with rotavirus vaccine) | Intervention Type: BIOLOGICAL; Name: yellow fever vaccine (YFV); Assigned to Arm(s): Group A (without rotavirus vaccine), Group B (with rotavirus vaccine) | Intervention Type: BIOLOGICAL; Name: meningitis conjugate vaccine (PsA-TT-5μg); Assigned to Arm(s): Group A (without rotavirus vaccine), Group B (with rotavirus vaccine)
C: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: D